Niacin
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Niacin: Towards Homozygous Familial Hypercholesterolaemia
One-Sentence Summary
Niacin (vitamin B3) is a long-established lipid-modifying agent, frequently referenced alongside statins, fibrates and other non-statin therapies in the management of dyslipidaemia. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolaemia (HoFH), with 2 clinical trials and 21 publications currently identified, though most of this evidence relates to the broader HoFH treatment landscape rather than niacin monotherapy specifically. Core regulatory and mechanistic data for niacin are currently missing from this evidence pack, so findings should be treated as preliminary.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the evidence pack (regulatory indication text unavailable); niacin is historically used as a lipid-modifying agent for dyslipidaemia |
| Predicted New Indication | Homozygous Familial Hypercholesterolaemia |
| TxGNN Prediction Score | 99.74% |
| Evidence Level | L2 (1 completed Phase 3 trial identified, not niacin-specific) |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for niacin is not available in this evidence pack, and no formal original indication text was supplied. Based on the literature evidence retrieved, niacin is well recognised as a non-statin lipid-lowering agent, historically used alongside statins, fibrates, bile acid sequestrants and n-3 fatty acids in the management of dyslipidaemia (PMID 24506448, PMID 26376908, PMID 23959229).
Homozygous Familial Hypercholesterolaemia is an extreme form of dyslipidaemia driven by absent or impaired LDL receptor function, resulting in markedly elevated LDL-C from birth. Because niacin’s established pharmacological effect is lipid modification, there is a plausible mechanistic rationale for its consideration in HoFH management, and it is already referenced in the HoFH pharmacotherapy literature as part of combination regimens (e.g. alongside lomitapide, PMID 24734312).
However, none of the identified clinical trials evaluate niacin directly in HoFH — the Phase 3 trial identified (NCT03510715) studies alirocumab, and the registry study (NCT03110432) is an observational dyslipidaemia registry. The literature support is therefore largely contextual (niacin as one option within the broader non-statin/HoFH treatment discussion) rather than direct evidence of niacin efficacy in HoFH specifically. This should be clarified before further action is taken.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrolment | Key Findings |
|---|---|---|---|---|
| NCT03510715 | Phase 3 | Completed | 18 | Evaluated alirocumab (not niacin) on LDL-C reduction in children/adolescents with HoFH; included as background HoFH treatment context |
| NCT03110432 | N/A (Registry) | Completed | 1,695 | German prospective registry of very-high cardiovascular-risk dyslipidaemia patients eligible for PCSK9 inhibitor use; observational, not niacin-specific |
Note: Neither trial directly evaluates niacin in HoFH; both provide disease-area context only.
Literature Evidence
| PMID | Year | Journal | Key Findings |
|---|---|---|---|
| 24734312 | 2014 | Pharmacotherapy | Pharmacokinetic interaction study of lomitapide with lipid-lowering therapies including niacin in HoFH management |
| 26376908 | 2015 | Arterioscler Thromb Vasc Biol | ATVB Council statement: RCTs show niacin monotherapy reduces cardiovascular disease endpoints |
| 24506448 | 2014 | Expert Rev Cardiovasc Ther | Review of non-statin treatments for dyslipoproteinemia, including niacin |
| 23959229 | 2013 | Nat Rev Cardiol | Review of lipid-lowering pharmacotherapies beyond statins |
| 26370207 | 2015 | Drugs | Review of diagnostic and treatment challenges in HoFH |
| 27797643 | 2016 | Metab Syndr Relat Disord | Review of modern management approaches for familial hypercholesterolaemia |
| 25257073 | 2014 | Atherosclerosis Suppl | Discussion of unmet needs and current achievements in HoFH treatment |
| 36422206 | 2022 | Medicina (Kaunas) | Literature analysis of FH diagnostics and treatment options |
| 2912428 | 1989 | Arteriosclerosis | Assessment of drug regimens (including resins) in children with heterozygous/homozygous FH |
| 20842562 | 2010 | Curr Treat Options Cardiovasc Med | Discussion of when and how to lower Lipoprotein(a), relevant to residual CVD risk in FH |
UK Market Information
Niacin currently has no marketing authorisation on record in this evidence pack — market status is Not Marketed, with 0 authorisations listed.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: Key warnings, contraindications and drug interaction data for niacin were not available in this evidence pack (flagged as a Blocking data gap — see Conclusion).
Conclusion and Next Steps
Decision: Hold
Rationale: No direct clinical trial evidence for niacin in HoFH was identified — the retrieved trials evaluate alirocumab and an observational registry, not niacin itself. Combined with the absence of mechanism-of-action data and safety/contraindication data (a Blocking-severity gap), this candidate cannot yet proceed to safety or efficacy assessment.
To proceed, the following is needed:
- TFDA/MHRA SmPC warnings and contraindications for niacin (Blocking gap, DG001)
- Documented mechanism of action for niacin (High-priority gap, DG002)
- Original regulatory indication text for niacin, to properly assess mechanistic similarity to HoFH
- Clinical trial or observational data evaluating niacin specifically (not combination regimens) in HoFH populations
- Reclassification of the literature evidence base (study type/relevance currently marked “pending”)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.